Living up to its motto “Fair Competition for Greater Good”, the CCI as a follow up on the investigation by its investigation arm, the Director General, has sought the basis of setting the rates of medicines and other medical devices. Coming in the wake of the 2021 report of CCI on ‘Market Study on the Pharmaceutical Sector in India’ showing huge profiteering and another PIL seeking enforcement of Clinical Establishment Rules, 2012 with the SC, seeking response from the Government and showing concern in the matter, it may be a step in the right direction.